Inovio Pharmaceuticals Inc. (NYSEMKT:INO) on May 30 announced that its previously announced 1-for-4 reverse stock split shall become effective at 5 P.M., Thursday, June 5, 2014, and trading of the Company’s common stock on a post-reverse split basis shall commence on Friday, June 6, 2014. Inovio Pharmaceuticals Inc. (NYSEMKT:INO) weekly performance is -74.45%. On last trading day company shares ended up $2.31. Analysts mean target price for the company is $4.80. Inovio Pharmaceuticals Inc. (NYSEMKT:INO) distance from 50-day simple moving average (SMA50) is -77.54%.
On May 7, 2014 Cleveland BioLabs, Inc. (NASDAQ:CBLI) adopted compensation arrangements pursuant to which its Chief Executive Officer, Yakov Kogan, Ph.D., and Chief Scientific Officer, Andrei Gudkov, Ph.D., D. Sci., each agreed to a 20% reduction in their original base salaries. In addition, both officers became eligible participants in the Company’s Severance Benefit Plan. These compensation arrangements became effective May 7, 2014. Cleveland BioLabs, Inc. (NASDAQ:CBLI) shares fell -4.58% in last trading session and ended the day on $0.496. CBLI return on assets is -52.00%.Cleveland BioLabs, Inc. (NASDAQ:CBLI) quarterly performance is -32.95%.
SIGA Technologies Inc. (NASDAQ:SIGA) was downgraded by Zacks from a “neutral” rating to an “underperform” rating in a note issued to investors on Monday, StockRatingsNetwork.com reports. They currently have a $2.70 price target on the stock. Zacks‘s price target suggests a potential downside of 2.00% from the company’s current price. SIGA Technologies, Inc. (NASDAQ:SIGA) shares moved up 1.57% in last trading session and was closed at $2.59, while trading in range of $2.49 – $2.66. SIGA Technologies, Inc. (NASDAQ:SIGA) year to date (YTD) performance is -20.80%.
Onconova Therapeutics, Inc. (NASDAQ:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, on 12 may provide a corporate update and reported financial results for the first quarter ended March 31, 2014. Total net revenue was $0.4 million for the first quarter of 2014, compared to $1.1 million for the first quarter of 2013. Onconova Therapeutics Inc. (NASDAQ:ONTX) ended the last trading day at $4.24. Company weekly volatility is calculated as 6.30% and price to cash ratio as 1.09.Onconova Therapeutics Inc. (NASDAQ:ONTX) showed a negative weekly performance of -17.19%.
Biota Pharmaceuticals Inc. (NASDAQ:BOTA) on 2 June said it plans to cut its workforce by about two-thirds and shut down its Melbourne, Australia, facility, following the loss of a key government contract. Biota Pharmaceuticals Inc. (NASDAQ:BOTA) net profit margin is -19.60% and weekly performance is -14.80%. On last trading day company shares ended up $2.36. Analysts mean target price for the company is $5.00. Biota Pharmaceuticals Inc. (NASDAQ:BOTA) distance from 50-day simple moving average (SMA50) is -45.05%.